Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes.
OBJECTIVE
To evaluate the extent of concomitant use of anticholinergic and cholinesterase inhibitor medications in Medicaid recipients with dementia residing in nursing homes.


METHODS
Cross-sectional survey of medical claims data.


METHODS
Indiana Medicaid claims for 2004.


METHODS
Indiana Medicaid recipients continuously eligible for Medicaid in 2004 aged 65 and older with dementia who were residing in nursing homes and taking cholinesterase inhibitors.


METHODS
Rates of concomitant anticholinergic and cholinesterase inhibitor use, number of days residents experienced concomitant use, and concomitant use according to therapeutic class and level of anticholinergic activity were determined.


RESULTS
A large proportion (46.7%) of 3,251 Medicaid beneficiaries living in nursing homes and taking cholinesterase inhibitors received anticholinergics concomitantly. Anticholinergics designated as Level 3, or having markedly anticholinergic adverse effects, accounted for most of the concomitant anticholinergic use. More than half (58.1%) of the individuals with concomitant anticholinergic use had 100 or more days of such use.


CONCLUSIONS
Nearly half of Indiana Medicaid recipients with dementia residing in nursing homes who were taking cholinesterase inhibitors in 2004 were using anticholinergics concomitantly. Patterns of concomitant use in the population examined may assist practitioners in reviewing their prescribing decisions for this vulnerable population.
Modi
Ankita
A
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, West Lafayette, Indiana 47907, USA.
Weiner
Michael
M
Craig
Bruce A
BA
Sands
Laura P
LP
Rosenman
Marc B
MB
Thomas
Joseph
J
D000368:Aged; D000369:Aged, 80 and over; D016009:Chi-Square Distribution; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003704:Dementia / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007196:Indiana; D008297:Male; D008484:Medicaid / Q000706:statistics & numerical data*; D009735:Nursing Homes; D012189:Retrospective Studies; D014481:United States
D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors